← Scroll for more →
Adma Biologics, Inc. (ADMA)
Biological Products, (No Diagnostic Substances)
Latest Price
$11.41
TTM P/E
16.30
Normalized P/E
44.06
TTM Div Yield
--
Fwd Div Yield
--
Book Value
1.76
P/B Ratio
6.48
Valuation metrics
adjust assumptions →EPS: $0.60
Book value / share: $2.01
Formula: √(22.5 × EPS × BVPS)
Graham Number
$5.20
56% downside
Base FCF: $28M (median of recent 5yr)
Growth: 5%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$2.06
82% downside
EPS: $0.60
Target P/E: 45×
Formula: EPS × P/E
P/E Fair Value
$27.00
+130% upside
Institutional Ownership
90.6% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 38.36M | $321.0M | 17.02% | +1.52M | 2026-06-30 |
| State Street Corp | 17.12M | $143.0M | 7.60% | +3.03M | 2026-06-30 |
| Vanguard Capital Management LLC | 10.10M | $84.0M | 4.48% | -203.1K | 2026-06-30 |
| Vanguard Portfolio Management LLC | 10.09M | $84.0M | 4.48% | +1.22M | 2026-06-30 |
| Rubric Capital Management LP | 9.34M | $78.0M | 4.14% | +7.53M | 2026-06-30 |
| Capital Research Global Investors | 8.76M | $73.0M | 3.89% | -2.43M | 2026-06-30 |
| First Trust Advisors LP | 7.80M | $65.0M | 3.46% | +7.44M | 2026-06-30 |
| Geode Capital Management, LLC | 6.06M | $50.0M | 2.69% | +235.9K | 2026-06-30 |
| Caligan Partners LP | 6.03M | $50.0M | 2.67% | +968.5K | 2026-06-30 |
| D. E. Shaw & Co., Inc. | 5.27M | $44.0M | 2.34% | +4.71M | 2026-06-30 |